Africa is grappling with severe food insecurity in the wake of consecutive droughts, climate change, and ongoing conflicts, ...

Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

The emergent field of CRISPR/Cas sensing technology is showing promise as a new paradigm in clinical diagnostics, although widespread clinical adoption remains limited. This perspective paper ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...